NXL
Nexalin Technology Inc.NASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$8.34M
P/E Ratio
—
EPS
$-0.50
Beta
4.23
52W High
$2.00
52W Low
$0.33
50-Day MA
$0.43
200-Day MA
$0.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nexalin Technology Inc.
Nexalin Technology Inc. is an innovative leader in the medical technology industry, dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. These non-invasive therapies target conditions such as anxiety, depression, and substance addiction, reflecting the company's commitment to advancing mental health solutions. With a robust foundation in research and a clear strategic focus on improving patient outcomes, Nexalin is well-positioned to leverage the increasing demand for cutting-edge healthcare innovations, indicating significant growth potential in the dynamic digital health marketplace.
Fundamentals
| Revenue (TTM) | 301,650 |
| Gross Profit (TTM) | 240,270 |
| EBITDA | $-8.37M |
| Operating Margin | -1404.00% |
| Return on Equity | -221.50% |
| Return on Assets | -118.40% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $0.20 |
| Price-to-Book | 2.34 |
| Price-to-Sales (TTM) | 27.63 |
| EV/Revenue | 16.72 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 533.00% |
| Shares Outstanding | $20.58M |
| Float | $17.86M |
| % Insiders | 11.23% |
| % Institutions | 5.99% |
Historical Volatility
HV 10-Day
132.65%
HV 20-Day
105.33%
HV 30-Day
93.34%
HV 60-Day
102.86%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($2.00 target)
1
Strong BuyData last updated: 4/28/2026